|Day Low/High||332.00 / 344.49|
|52 Wk Low/High||281.89 / 416.49|
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Regeneron Pharmaceuticals, Inc. , where a total of 5,281 contracts have traded so far, representing approximately 528,100 underlying shares.
* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.
Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.
Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
Among 13 Alliance presentations, a late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response
- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
- ESMO data demonstrate breadth of joint Regeneron and Sanofi immuno-oncology development program
Straying from these names could land you in quicksand as the 4th quarter begins.
* Libtayo is the third anti-PD-1 approved in the U.S.
* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy
Jim Cramer looks at the investment strategies you and your family need to employ throughout your life.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.